Valemetostat

Valemetostat
Clinical data
Trade names	Ezharmia
Other names	Valemetostat tosilate (JAN); DS-3201; DS-3201b
Identifiers
	IUPAC name (2R)-7-Chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide;
CAS Number	1809336-39-7 1809336-93-3 (tosylate);
PubChem CID	126481870;
UNII	60RD0234VE;
KEGG	D11662;
Chemical and physical data
Formula	C26H34ClN3O4
Molar mass	488.03 g·mol−1

Valemetostat (trade name Ezharmia) is a drug used for the treatment of adult T-cell leukemia/lymphoma (ATL).

Quick facts Clinical data, Trade names ...

Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2), which are implicated in the etiology of some forms of cancer including non-Hodgkin lymphomas.^[1]^[2]

In Japan, valemetostat was approved in September 2022 for patients with relapsed or refractory adult T-cell leukemia/lymphoma.^[3]^[4]

References